NCT05788744Recruiting
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 23 Nov 2022
- Start date
- 1 Jan 2023
- Primary completion date
- Jan 2029
- Lead sponsor
- Copenhagen University Hospital at Herlev
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT05788744
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 1 Jan 2023 to the primary completion date, Jan 2029
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
Other
- Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Who the study is looking for
- Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
- Sub-study 2: .
- PDAC tumor stage I-III
- Has received intended curative resection (R0/R1) of PDAC
- No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation
Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg Universitetshospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
| Aarhus Universitetshospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
| Copenhagen University Hospital, Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
| Copenhagen University Hospital Herlev and Gentofte Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
| Odense Universitetshospital Coordinator of this site? Confirm its status | Odense | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.